

A Simple Method to Measure Baseline Occupancy of Neostriatal Dopamine D₂ Receptors by Dopamine *In Vivo* in Healthy Subjects

N.P.L.G. Verhoeff, M.D., Ph.D., S. Kapur, M.D., Ph.D., D. Hussey, B.Sc., M. Lee, B.Sc., B. Christensen, Ph.D., C.Psych., G. Papatheodorou, M.D., and R.B. Zipursky, M.D.

The effect of endogenous dopamine (DA) on measurement of neostriatal DA D₂ receptor binding potential (D₂RBP) *in vivo* was evaluated with positron emission tomography (PET) and the radiotracer [¹¹C]raclopride by comparing the D₂RBP before and after acute DA depletion. DA depletion was achieved by per-oral administration of 4.5 g α -methyl-para-tyrosine (AMPT) given in 25 h. Six healthy subjects completed the protocol. The AMPT treatment increased D₂RBP significantly from 3.11 ± 0.25 to 3.68 ± 0.23 and decreased plasma levels of the DA metabolite homovanillic acid by $71 \pm 11\%$ and levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenylethylglycol by 53

$\pm 7\%$. Increase in D₂RBP correlated with decrease in attentiveness and with increase in errors of commission from Conners' Continuous Performance Test. On AMPT, a significant decrease in subjective happiness scores was observed. The results imply that a noninvasive [¹¹C]raclopride PET protocol coupled with relatively brief administration of a rather low total dose of AMPT resulted in measurable acute DA depletion that might provide estimates of synaptic neostriatal DA concentration. [*Neuropsychopharmacology* 25:213–223, 2001] © 2001 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

KEY WORDS: Dopamine; Dopamine D₂ receptors; [¹¹C]raclopride; Positron emission tomography; α -methyl-para-tyrosine; *In vivo* binding

Endogenous dopamine (DA) levels have recently been estimated in humans *in vivo* with positron emission tomography (PET) and with single photon emission com-

puted tomography (SPECT). DA levels during stimulant-induced release have been estimated by comparing radiotracer binding at baseline and after amphetamine or methylphenidate challenges using PET and the DA D₂ receptor (D₂R) radiotracer [¹¹C]raclopride (Volkow et al. 1994; Breier et al. 1997) as well as SPECT and [¹²³I](S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide ([¹²³I]IBZM) (Booij et al. 1997; Abi-Dargham et al. 1998). DA levels during baseline release have been estimated by comparing radiotracer binding at baseline and after a rapid DA depletion induced by the competitive and reversible tyrosine hydroxylase inhibitor α -methyl-para-tyrosine (AMPT) (Engelman et al. 1968) using SPECT and [¹²³I]IBZM (Laruelle et al. 1997; Abi-Dargham et al. 2000) or [¹²³I]epidepride (Fujita et al. 2000).

From the PET Centre and Schizophrenia and Continuing Care Division, Clarke Site, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.

Address correspondence to: Nicolaas Paul L.G. Verhoeff, M.D., F.R.C.P.C., Ph.D., Clinical Research Fellow Psychiatry, Centre for Addiction and Mental Health, Clarke Site, PET Centre, 250 College Street, Toronto, Ontario M5T 1R8, Canada.

Received August 31, 2000; revised December 22, 2000; accepted January 9, 2001.

One recent [^{123}I]IBZM SPECT study showed a larger increase in neostriatal D_2R availability with AMPT-induced DA depletion in 18 untreated schizophrenic patients compared to 18 matched controls (Abi-Dargham et al. 2000). These findings, which suggest that schizophrenic patients have elevated neostriatal DA levels, will need to be replicated in independent studies. In order to be able to do this with PET, we implemented a modified protocol for AMPT-induced DA depletion using the simplified 3-parameter reference tissue model (SRTM) (Lammertsma and Hume 1996) which only requires 60 min dynamic PET scanning following a bolus injection of [^{11}C]raclopride. The good response of [^{11}C]raclopride to changes in extracellular DA makes this tracer, so far, a good candidate for the PET measurement of changes in synaptic DA levels (Moresco et al. 1999; Laruelle 2000). This PET study design required more work before injection of the tracer and more effort analyzing the results after the data were acquired, but was very patient friendly, in contrast to the previously applied bolus infusion technique that required less work before and after imaging data acquisition, but that was not so patient friendly (Laruelle et al. 1997; Abi-Dargham et al. 2000).

In the two previous DA depletion imaging studies in healthy subjects, 8 g AMPT was administered over two days (Laruelle et al. 1997; Abi-Dargham et al. 2000), and 5.5 g/70 kg body weight of AMPT were given over 37 hours in a third study (Fujita et al. 2000). In the 67 healthy subjects who participated in these three studies, the following adverse effects were attributed to AMPT: eight developed acute dystonias, six had akathisia of sufficient severity to warrant psychotropic medication, four developed crystalluria, two showed significant increases in dysphoric mood states (anxiety and tension), and one diarrhoea. The administration of AMPT orally 1 g, t.i.d. for 24 hours has been reported to result in minimum levels of the DA metabolite homovanillic acid (HVA) and of the norepinephrine (NE) metabolite 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) (Anand et al. 1999). HVA depletion following AMPT has been reported to reflect neostriatal DA depletion (Mignot and Laude 1985; Laruelle et al. 1997). Therefore, in order to prevent serious adverse effects of AMPT but still obtain adequate DA depletion, we decided to reduce the total amount of AMPT administered to 4.5 g orally over 28 hours. AMPT plasma levels were measured to assess whether this dosing regimen resulted in a sufficient AMPT concentration to substantially inhibit tyrosine hydroxylase (Laruelle et al. 1997). The amount of catecholamine depletion was also estimated by measuring plasma levels of HVA, MHPG and prolactin.

Previously AMPT has been reported to induce not only acute dystonias in a minority but also mild signs of Parkinsonism in the majority of healthy subjects (Laruelle et al. 1997; Abi-Dargham et al. 2000; Fujita et

al. 2000). We, therefore, monitored our subjects regularly for possible extrapyramidal symptoms. Since AMPT was reported to affect subjective feelings in healthy subjects with significant decreases in happiness and increases in sleepiness and restlessness (McCann et al. 1993; Laruelle et al. 1997), subjects reported subjective feelings both in a continuous visual analog and in an ordinal scale fashion.

As alterations in DAergic transmission may be involved in selective attention (Servan-Schreiber et al. 1998), this was tested in the healthy subjects at baseline and at different stages of AMPT-induced DA depletion. A finger tapping task was included in order to control for possible effects of DA depletion on motor speed. Since self-reported sleepiness during AMPT depletion has been reported to be a good predictor of poor performance on cognitive tests (McCann et al. 1992), objective ratings were obtained for sedation during each series of cognitive tests.

MATERIALS AND METHODS

Human Subjects

The study was approved by the Human Subjects Review Committee of the University of Toronto and has been carried out in accordance with the Helsinki Declaration of 1975. Five men and three women, age 27 ± 5 years (all values in this article are expressed as average \pm standard deviation) and all right-handed, entered the study. Exclusion criteria were: 1) psychiatric diagnosis on Axis I as assessed by the Structured Clinical Interview for DSM-IV, nonpatient version; 2) serious medical or neurological illness or significant head injury by history or on physical examination or based on laboratory studies (complete blood count, fasting blood glucose, basic urea nitrogen, creatinine, electrolytes, thyroid function tests, liver function tests, urinalysis, EKG); 3) lifetime history of alcohol or substance dependence; 4) history of alcohol or substance abuse during the six months preceding the study; 5) recent substance use on urine toxicology screen; 6) treatment with any psychotropic medications by history or on urine toxicology screen; and 7) pregnancy by history or on urine βHCG test.

Depletion Regimen and Clinical Monitoring

Each subject was scanned twice, in the baseline state (PET1, day 1) and after DA depletion (PET2, day 3). DA depletion was induced by oral administration of in total 4500 mg AMPT over 25 hours. AMPT was administered orally in doses of 750 mg each at the following times: at 10AM, 1.30PM, 6PM, and 10PM on day 2, and at 7AM and 11AM on day 3. During AMPT administration, subjects remained under direct observation at the PET Centre during the day and on a psychiatric inpatient

unit during the night. To prevent the formation of AMPT crystals in the urine, subjects were instructed to drink at least 4 L of fluids per day, starting on day 2 (Engelman et al. 1968). In addition, in order to alkalinize the urine which increased AMPT solubility, sodium bicarbonate 1.2 g orally was given at 10 p.m. on day 1 and at 7 a.m. on day 2. Urine samples were collected at 3 p.m. on day 2 and at 7 a.m. on day 3 to examine the presence of AMPT crystals.

Subjects were evaluated five times using clinical rating scales for adverse effects and mood states pre AMPT (on day 1 and on day 2) and post AMPT (cumulative oral doses of 750 mg on day 2, and 3750 mg and 4500 mg on day 3). The presence of adverse effects such as parkinsonian symptoms, acute dystonias, and abnormal involuntary movements, was monitored using the Extrapyramidal Symptom Rating Scale (ESRS) (Chouinard et al. 1980). The subjects rated 19 subjective feelings on a continuous visual analog scale (VAS) ranging from 0% ("not at all") to 100% ("most ever"). Subjective feelings were also rated using the ordinal Profile Of Mood States (POMS) (McNair et al. 1981). In addition, subjects rated depressive symptoms using the Beck Depression Inventory, Short Form (BDI) (Beck et al. 1974).

The subjects performed the Conners' Continuous Performance Test (CPT) (Conners 1995) and the Finger Tapping Test (FTT) (Reitan and Wolfson 1985) pre AMPT (day 1), post 1500 mg AMPT (day 2), and post 3750 mg AMPT (day 3). The FTT was applied using a Finger Tapper board (Psychological Assessment Resources, Inc., Odessa, FL). After one 10-second practice trial for each hand, 10-second trials were administered alternating between the right and left hand, allowing for a 15-second rest period between trials for each hand. Trials were administered until five consecutive trials rendered scores within a five-tap range, and average scores of these five trials were obtained. If this criterion was not reached, 10 trials were administered and average scores of these 10 trials were obtained. Subjects were rated during these tests regarding level of sedation using the Observer's Assessment of Alertness/Sedation Scale (OAASS) (Chernik et al. 1990).

Catecholamine Metabolites Plasma Analysis

Plasma HVA and MHPG samples were collected at 10 a.m. (day 1), at 10 a.m. (day 2 pre AMPT), at 3 p.m. (day 2 post 1500 mg AMPT), and at 1 p.m. (day 3 post 4500 mg AMPT).

Plasma HVA levels were measured as the methylated then acetylated derivative using Gas Chromatography-Mass spectrometry (GCMS) with selected ion monitoring (Warsh et al. 1987). Plasma MHPG levels were measured as the 4-acetyl-di-trifluoro-acetyl derivative using GCMS with selected ion monitoring (Takahashi et al. 1977).

AMPT Plasma Analysis

Plasma AMPT samples were collected at 10 a.m. (day 1), at 10 a.m. (day 2 pre AMPT), at 3 p.m. (day 2 post 1500 mg AMPT), and at 1 p.m. (day 3 post 4500 mg AMPT). Plasma AMPT concentrations were measured as the pentafluorobenzoyl derivative using GCMS with selected ion monitoring (Roy et al. 1984).

Prolactin Plasma Analysis

Plasma prolactin samples were collected at 10 a.m. (day 1), at 10 a.m. (day 2 pre AMPT), at 3 p.m. (day 2 post 1500 mg AMPT), and at 1 p.m. (day 3 post 4500 mg AMPT). Plasma prolactin levels were measured using microparticle enzyme immunoassay technology (Abbott Laboratories 1997).

[¹¹C]raclopride PET Data Acquisition

PET images were obtained with a GEMS PC2048-15B camera (General Electric Medical Systems, Milwaukee, WI) in five 1-minute frames followed by twenty 2-minute frames and three 5-minute frames after [¹¹C]raclopride bolus injection (pre AMPT: 370 ± 34 MBq (9.99 ± 0.93 mCi), specific activity 53,095 ± 17,649 GBq/mmol (1435 ± 477 Ci/mmol); post AMPT: 385 ± 42 MBq (10.41 ± 1.14 mCi), specific activity 56,795 ± 18,648 GBq/mmol (1535 ± 504 Ci/mmol)). There was no significant difference in the pre- and post-AMPT injected radioactivity and specific activity (two-tailed paired Student's *t*-test: *df* = 5, *p* = .552 and *p* = .673, respectively). The images were corrected for attenuation with a ⁶⁸Ge transmission scan and reconstructed using filtered back projection (Hanning filter, 5 mm full width at half maximum) and fifteen 6.5 mm-thick transaxial slices were obtained (total axial field of view 9.75 cm; covering area from the canto-meatal line upwards; part of cerebral cortex from vertex downward not covered).

Image Analysis

Regions of interest (ROIs) were manually drawn following the contour of the striata (pre AMPT: 3371 ± 465 mm³; post AMPT: 3202 ± 553 mm³) and cerebellum (pre AMPT: 13893 ± 1549 mm³; post AMPT: 13698 ± 1264 mm³) on two adjacent transaxial PET slices. There were no significant differences in the pre- and post-AMPT sizes of the ROIs of the striata and cerebellum (two-tailed paired Student's *t*-test: *df* = 5, *p* = .394 and *p* = .819, respectively). For [¹¹C]raclopride PET data, ROIs selected from the PET images have been shown to be almost identical to those obtained from coregistered MRI images (Wang et al. 1996a).

The neostriatal DA D₂ receptor binding potential (D₂RBP), the product of the total D₂R density (B_{max}), and

the affinity ($1/K_d$) of [^{11}C]raclopride for D_2R , were calculated using the SRTM (Lammertsma and Hume 1996). For [^{11}C]raclopride PET data, the SRTM has been shown to provide similar results as the 4-parameter reference tissue model (Lammertsma and Hume 1996), whereas the 4-parameter reference tissue model produced similar results as 1- and 2-tissue compartment models requiring metabolite-corrected plasma curves (Lammertsma et al. 1996; Ito et al. 1998) and as the sustained equilibrium method after bolus plus continuous infusion (Ito et al. 1998). The SRTM was applied using a flexible kinetic modeling tool (Burger and Buck 1997) which also allowed us to construct parametric D_2RBP images (Gunn et al. 1997). The parametric D_2RBP images were spatially normalized within the standard Montreal Neurologic Institute brain space using Statistical Parametric Mapping version 99 (SPM99) (Friston et al. 1995) and the D_2R ligand specific template technique (Meyer et al. 1999).

Outcome Measures

Our method is based on the finding that endogenous DA competes with the binding of [^{11}C]raclopride. When tracer amounts of high-specific activity [^{11}C]raclopride are injected and approach equilibrium, the ratio of the [^{11}C]raclopride bound specifically to the D_2R (S_{rac}) to that which is free in the extracellular fluid close to the D_2R (F_{rac}) is equal to the product of B_{max} times $1/K_d$, provided there is no endogenous DA:

$$\frac{S_{rac}}{F_{rac}} = \frac{B_{max}}{K_d} = \frac{\text{Number of } D_2 \text{ receptors}}{1/\text{Affinity of raclopride for } D_2 \text{ receptors}} = D_2RBP$$

As F_{rac} cannot be measured directly, this is estimated from the count rate density (i.e., F_{rac} plus nonspecific binding) in the cerebellum, a brain region almost devoid of D_2R (Martres et al. 1985). However, *in vivo* the endogenous DA competes with [^{11}C]raclopride for the D_2R . This competition can be represented as:

$$D_2RBP_{baseline} = \frac{S_{rac}}{F_{rac}} = \frac{B_{max}}{K_d(1 + DA_{conc}/K_i)}$$

where $D_2RBP_{baseline}$ = D_2RBP measurement at baseline, DA_{conc} = neostriatal DA concentration, and K_i = equilibrium inhibitory constant for DA regarding inhibition of raclopride binding.

However, $D_2RBP_{baseline}$ is confounded by endogenous DA. If one depletes DA and thereby removes the competition and the DA_{conc} term in the denominator, one can obtain a more accurate estimate of D_2RBP ($D_2RBP_{depleted}$). Therefore, under DA depletion, equation 2 functionally becomes:

$$D_2RBP_{depleted} = \frac{S_{rac}}{F_{rac}} = \frac{B_{max}}{K_d(1 + 0/K_i)} = \frac{B_{max}}{K_d}$$

The foregoing discussion illustrates that: 1) $D_2RBP_{baseline}$ is confounded by endogenous DA, and the higher the concentration of DA the lower the value of D_2RBP that will be obtained; 2) $D_2RBP_{depleted}$ more accurately reflects the true status of D_2R ; 3) by combining equations 2 and 3 it can be shown that the fractional increase in D_2RBP [i.e., $(D_2RBP_{depleted} - D_2RBP_{baseline})/D_2RBP_{baseline} = D_2RBP_{shift}$] is linearly proportional to the baseline DA_{conc} , provided the process of DA depletion does not change the number and affinity of the D_2R . Thus, D_2RBP_{shift} , under appropriate assumptions, is a semiquantitative index of endogenous DA levels.

Statistical Analyses

Data were monitored for meeting the criteria for a normal distribution by testing for skewness, curtosis and outliers, and for homogeneity of variance (Tabachnick and Fidell 1996). Correlations between PET data and clinical parameters were tested for using Pearson's product-moment correlation coefficient (r) if the criteria for a normal distribution were met and using Spearman's rank correlation coefficient (Rho) if these criteria were not met. AMPT effects on clinical ratings and plasma levels were assessed by repeated measures ANOVA, if the criteria for a normal distribution and homogeneity of variance were met and by Friedman's test if these criteria were not met. Similarly, AMPT effects on PET measurements were assessed by two-tailed paired Student's t -tests if the criteria were met and by Wilcoxon's signed ranks test if the criteria were not met. All tests were 2-tailed and probability values of 0.05 were used as the significance level. No corrections for multiple comparisons were applied. Statistical analyses were performed with SPSS for Windows, release 10.0.0 (SPSS Inc., Chicago, IL, 1999).

For the parametric D_2RBP images the equivalent of a 2-tailed paired Student's t -test pre versus post AMPT was done using SPM99. This was done because: 1) increased uptake has been observed in similar extrastriatal regions with [^{11}C]raclopride PET (Wang et al. 1993) as with [^{123}I]epidepride SPECT (Fujita et al. 2000), suggesting visualization of extrastriatal D_2R ; 2) decrements in uptake in some of those regions (i.e., in the thalamus and temporal insula) have been reported with age, in concordance with the D_2R decline with age in those regions observed *post mortem* (Wang et al. 1996b); and 3) baseline occupancy of extrastriatal D_2R by dopamine has been demonstrated using [^{123}I]epidepride SPECT and AMPT-induced dopamine depletion (Fujita et al. 2000).

As SPM has been reported to be successful in detecting receptor changes in brain areas that were not defined a priori (Weeks et al. 1997), this technique might help us in




Figure 1. Comparison of neostriatal dopamine D₂ receptor binding potential (D₂RBP), determined from Positron Emission Tomography data obtained from 0 to 60 min after [¹¹C]raclopride bolus injection, in six healthy subjects pre versus post AMPT. In each subject, the D₂RBP post AMPT was larger than pre AMPT (2-tailed paired t-test: $t = -22.666$, $p < .001$).

detecting possible increases in extrastriatal D₂RBP post AMPT. No global normalization was carried out. This provided a comparison between groups of the D₂RBP values. A threshold of 80%, discarding all values smaller than 80% of the whole brain average D₂RBP value, was used to delineate gray matter voxels. Corrected p -values $< .05$ at cluster or voxel level were considered significant.

RESULTS

Compliance with Protocol

Four men and two women, age 27 ± 6 years (average \pm s.d.) completed the protocol. A 30-year-old man and a 24-year-old woman initiated the study but did not complete the protocol. The man left due to mild symptoms (moderate dizziness when standing up, mild restlessness, mild hand tremors and mild slowness of movement) and the woman left the study as she did not like the overnight stay in the psychiatric inpatient unit.

[¹¹C]raclopride PET

The D₂RBP, obtained using manually drawn ROIs, was 3.11 ± 0.25 at baseline and increased significantly to

3.68 ± 0.23 post AMPT (paired t-test: $t = -22.666$, $df = 5$, $p < .001$) (Figure 1). The D₂RBP_{shift} was 0.185 ± 0.030 .

The analysis of the parametric D₂RBP images in SPM99 showed two clusters of significant change at the levels of the right and left striatum, respectively (corrected p -values for both clusters $< .0001$) (Figure 2). No significant differences at cluster or voxel level were observed in any other brain regions.

A negative correlation was observed between age and D₂RBP_{baseline} ($r = -0.941$, $p = .005$). This correlation with age persisted for D₂RBP_{depleted} ($r = -0.833$; $p = .040$) since D₂RBP_{baseline} and D₂RBP_{depleted} were positively correlated ($r = 0.969$, $p = .001$). There was a trend for a negative correlation between D₂RBP_{shift} and D₂RBP_{baseline} ($r = -0.788$, $p = .063$).

Plasma Measurements

Plasma Catecholamine Metabolites. Effects of AMPT on plasma HVA and MHPG levels are shown in Table 1. The AMPT-induced decrease in plasma HVA was significantly larger than that in MHPG (paired t-test, $df = 5$, $t = 4.409$, $p = .007$).

Plasma AMPT. AMPT levels were 10 ± 3 $\mu\text{g/mL}$ on day 2 post 1500 mg AMPT and 21 ± 12 $\mu\text{g/mL}$ on day 3 post 4500 mg AMPT.

Plasma Prolactin. Effects of AMPT on plasma prolactin levels are shown in Table 1. AMPT significantly increased plasma prolactin.

Clinical Effects of AMPT

Only very mild Parkinsonian symptoms and akathisia were induced by AMPT in three of our subjects. No acute dystonias or abnormal involuntary movements were observed. Effects of AMPT on VAS scores are shown in Table 2. On AMPT, scores for happiness were significantly decreased whereas scores for tiredness, sleepiness and drowsiness were significantly increased. There was a tendency for subjects to feel less energetic on AMPT whereas scores for hungeriness were quite variable at different times without a clear dose dependence on AMPT. No significant changes on AMPT were observed for the other VAS scores, in order of decreasing significance: talkative, depressed, anxious, high, nervous, sad, irritable, calm, mellow, fearful, mania, restless, and angry. Percentage decrease in happiness scores was significantly correlated to percentage MHPG decrease ($r = 0.935$, $p = 0.006$) but not to percentage HVA decrease or to D₂RBP_{shift}.

None of six dimensions derived from POMS scores (in order of decreasing significance: vigor, confusion, fatigue, tension, depression, and anger) changed significantly on AMPT. BDI scores were very low and did not change with AMPT treatment.




Figure 2. Results from the Statistical Parametric Mapping 99 analysis of the parametric dopamine D₂ receptor binding potential (D₂RBP) images in six healthy subjects pre versus post AMPT determined from Positron Emission Tomography data obtained from 0 to 60 min after [¹¹C]raclopride bolus injection. Transaxial slices of spatially normalized brains within the standard Montreal Neurologic Institute brain space in standard neurological orientation. The slices are parallel to and from 2 mm to 18 mm above the intercommissural line. Voxels with significant T statistics (corrected *p*-values < .05), indicating significant D₂RBP increases post versus pre AMPT, are indicated in hot color scale (ranging from 0–20 for the T statistic values).

Effects of AMPT on cognitive test performance are shown in Table 3. The OAASS overall scores decreased significantly on AMPT. Significant effects of AMPT on several CPT items were observed: Number of Commissions and Hit Response Time Standard Error increased whereas Attentiveness (*d'*) decreased. Other CPT items showed trends for significance on AMPT: Hit Response Time Change over Inter Stimulus Intervals and the

Overall Index increased. The remaining CPT items did not show any (trend for) significant change on AMPT.

D₂RBP_{shift} was significantly correlated with percentage increase in Number of Commissions (*r* = 0.837, *p* = .038) and with percentage decrease in Attentiveness (*d'*) (*r* = 0.890, *p* = .018). No significant AMPT-induced

Table 1. Effect of AMPT Administration on Various Plasma Levels

Plasma Level	Baseline	AMPT 1500 mg	AMPT 4500 mg	Significance of Change*
HVA (nmol/L)	93 ± 35	38 ± 11	25 ± 10	0.002 [^]
MHPG (nmol/L)	60 ± 23	50 ± 16	28 ± 10	<0.001
Prolactin (µg/L)	11 ± 2	47 ± 24	30 ± 13	0.003

Levels of significance of change in plasma levels over three cumulative oral doses of AMPT: 0 mg (average of two measurements per subject), 1500 mg, and 4500 mg (one measurement each per subject). Values expressed as mean ± standard deviation. For calculation of % change, the average baseline value of each subject was considered to be 100%.

**P*-values from repeated measured ANOVA (if data met criteria for normal distribution) are not marked, whereas *p*-values from Friedman's test (if data did not meet criteria for normal distribution) are marked with [^].

Table 2. Effect of AMPT on Subjective Mood Ratings with the Visual Analog Scale

VAS Item	Baseline	AMPT 750 mg	AMPT 3750 mg	AMPT 4500 mg	Significance of Change*
Happy	68 ± 13	55 ± 19	40 ± 27	40 ± 30	0.002
Tired	41 ± 22	57 ± 37	71 ± 36	32 ± 26	0.025
Sleepy	46 ± 23	64 ± 27	73 ± 37	41 ± 29	0.041
Drowsy	42 ± 18	59 ± 26	74 ± 37	48 ± 29	0.052
Hungry	19 ± 24	5 ± 10	36 ± 30	15 ± 19	0.084 [^]
Energetic	49 ± 14	27 ± 21	35 ± 22	49 ± 18	0.096

Levels of significance of change in VAS mood ratings over four cumulative oral doses of AMPT: 0 mg (average of two measurements per subject), 750 mg, 3750 mg, and 4500 mg (one measurement each per subject). Values expressed as mean ± standard deviation.

**P*-values from repeated measured ANOVA (if data met criteria for normal distribution) are not marked, whereas *p*-values from Friedman's test (if data did not meet criteria for normal distribution) are marked with [^].

Table 3. Effect of AMPT on Cognitive Test Performance

Cognitive Test Item	Baseline	AMPT 500 mg	AMPT 3750 mg	Significance of Change*
Sedation				
OAASS total score	5.0 ± 0.0	4.5 ± 0.5	4.0 ± 0.0	0.011 [^]
Conners CPT				
Number of Commissions	8 ± 6	7 ± 3	13 ± 5	0.011
Hit Response Time SE	4.91 ± 0.89	5.37 ± 0.93	6.18 ± 1.44	0.055
Attentiveness (d')	3.60 ± 0.75	3.39 ± 0.41	2.68 ± 0.47	0.061
Hit RT ISI Change	0.05 ± 0.03	0.06 ± 0.03	0.08 ± 0.03	0.073
Overall index	3.33 ± 3.98	2.52 ± 6.17	6.79 ± 7.74	0.092 [^]

Levels of significance of change in plasma levels over three cumulative oral doses of AMPT: 0 mg (average of two measurements per subject), 1500 mg, and 4500 mg (one measurement each per subject). Values expressed as mean ± standard deviation.

**P*-values from repeated measured ANOVA (if data met criteria for normal distribution) are not marked, whereas *p*-values from Friedman's test (if data did not meet criteria for normal distribution) are marked with [^].

changes or correlations with age were noted on FTT scores (left and right index fingers).

DISCUSSION

[¹¹C]raclopride PET

An 18.5 ± 3.0% neostriatal D₂RBP increase was observed in the six subjects who completed the AMPT DA depletion protocol. This is in accordance with D₂RBP increases reported with [¹²³I]IBZM SPECT in two independent samples: 28 ± 16% in nine healthy subjects 25 ± 4 years old (Laruelle et al. 1997) and 9 ± 7% in 18 healthy subjects 31 ± 8 years old (Abi-Dargham et al. 2000).

Assuming partial depletion, we estimated a DA_{conc} of 27 ± 6 nM [by multiplying the DA_{conc} calculated assuming full depletion and taking for K_i a value of 100 nM (Fisher et al. 1995; Ginovart et al. 1997), with HVA_{PET1}/(HVA_{PET1}-HVA_{PET2}) (Laruelle et al. 1997)]. Estimations *in vivo* for the DA_{conc} have been 40–60 nM in mice (Ross and Jackson 1989), 51–56 nM in Cynomolgus monkeys (Ginovart et al. 1997), 45 ± 25 nM (assuming full depletion) to 72 ± 40 nM (assuming partial depletion) in humans (Laruelle et al. 1997). Based on a literature review, the average DA_{conc} in humans has been estimated to be 100 nM at baseline and 200 nM during activation (Fisher et al. 1995). Therefore, our estimation of the DA_{conc} at baseline is in the same order of magnitude as estimations from the literature. However, caution should be exercised when estimating the baseline DA_{conc} from the D₂RBP_{shift} as we did in this study, since at least eight potential *in vivo* modulators of the D₂RBP_{shift} must be considered.

1. The AMPT dose used in our study may not have resulted in optimum DA depletion with minimal adverse effects. Our dose rate was similar to the 1 g PO

q.i.d. administered by Laruelle et al. (1997) and Abi-Dargham et al. (2000), whereas the duration was similar to the 24 hours suggested by Anand et al. (1999). We performed clinical ratings and plasma metabolite measures at various points during our study to monitor the effect of various total dosages of AMPT. Validation of these preliminary results may require producing placebo-controlled dose response curves.

- In our study, the order of PET scanning at baseline and with DA depletion was not randomized. This because of a possible carry-over effect if PET on AMPT depletion would have been done first. Thus, we cannot fully rule out a time or order effect on our imaging data.
- The neostriatal D₂RBP increase after AMPT administration might have reflected D₂R upregulation rather than removal of endogenous DA. However, previous animal studies indicated that dopamine depletion for two days did not cause receptor upregulation. In rodents, DA depletion induced by reserpine (Ross and Jackson 1989), 6-hydroxydopamine (Iwata et al. 1992; Hume et al. 1995; Narang and Wamsley 1995) or AMPT (Laruelle et al. 1997) did not cause any significant neostriatal D₂R upregulation in two days to three weeks. In Cynomolgus monkeys, reserpine-induced DA depletion did not change B_{max} *in vivo* (Ginovart et al. 1997). Given the brief duration of our AMPT administration protocol, receptor upregulation does not seem to have contributed to the D₂RBP increase.
- Differences in neostriatal D₂RBP increase could reflect different proportions of high- and low-affinity state D₂R. In general, agonists predominantly label high-affinity state and antagonists label both high- and low-affinity state D₂R (Sibley et al. 1982). The proportion of these two states varies among brain regions (Camps et al. 1989) and may differ *in vivo* from *in vitro* (Richfield et al. 1986).

5. It is generally believed that agonists cause internalization of D₂R (Ito et al. 1999), which *in vivo* results in an increased affinity for butyrophenones and in a decreased affinity for benzamides (Laruelle 2000). The latter may be due to the changed internal milieu with D₂R internalization such as decreasing sodium and increasing proton concentrations which are both known to decrease the affinity of benzamides for D₂R (Laruelle 2000). It is unlikely to be due to decreased access of benzamides to internalized D₂R since all effective neuroreceptor ligands must pass the blood brain barrier, which is essentially composed of a lipophilic membrane. Thus, such tracers should pass the plasma membrane and have access to internalized receptors. This is supported by data showing that [¹²³I]IBZM diffuses well within peripheral blood cells in humans *in vivo* (Costa et al. 1990).
6. There may be interindividual differences in pharmacodynamic effects of AMPT on tyrosine hydroxylase. In fact, four isoforms of this enzyme were found in human brain showing different regional distributions (Lewis et al. 1993).
7. A significant number of D₂R are located extrasynaptically (Khan et al. 1998) where the DA concentration is lower than in the synapse (Fisher et al. 1995). Thus, DA may occupy a smaller percentage of extrasynaptic receptors compared to those within the synapse and there may be interindividual differences in the proportion of synaptic versus extrasynaptic D₂R.
8. Benzamides label both dimers and monomers of D₂R whereas butyrophenones label only monomers (Verhoeff 1999; Laruelle 2000). However, the actual relationship between D₂R oligomeric states, D₂R internalization and vulnerability to endogenous DA competition has to our knowledge not been documented (Laruelle 2000).

We observed a negative correlation between age and neostriatal D₂RBP at baseline which was preserved after DA depletion. Negative correlations between age and neostriatal D₂RBP have been consistently reported in imaging studies of healthy subjects in which endogenous DA competed with the radiotracers used (Verhoeff 1999). The preliminary findings in our study suggest that these negative correlations may remain valid with DA depletion.

A trend for a negative correlation between D₂RBP_{shift} and D₂RBP_{baseline} was observed both in our study and by Laruelle et al. (1997). This suggests that a relatively high D₂R occupancy by DA might contribute to a relatively low D₂RBP_{baseline}.

Plasma Catecholamine Metabolites

The AMPT-induced decreases in plasma HVA by 71 ± 11% and in plasma MHPG by 53 ± 7% in our study are

compatible with the decreases of 70 ± 12% and 66 ± 6%, respectively, obtained by Laruelle et al. (1997) and with the decreases of 64 ± 11% and 51 ± 11%, respectively, observed by Fujita et al. (2000).

Plasma AMPT

The AMPT levels in our study were 21.1 ± 11.7 µg/mL prior to PET2. These values are compatible with the steady-state levels of 21 ± 7 µg/mL obtained by Laruelle et al. (1997) and 21.4 ± 8.0 µg/ml obtained by Fujita et al. (2000).

Plasma Prolactin

The AMPT-induced increases in plasma prolactin by 340 ± 249% on day 2 and by 176 ± 118% on day 3 were larger than the 93 ± 56% (rested) and 152 ± 86% (sleep-deprived) increases observed post 5250 mg AMPT over a 33-hour period in 40 healthy male volunteers (McCann et al. 1992). The increases in prolactin in our study were larger in the two women (range on day 2: 241–820% ; on day 3: 204–390%) than in the four men (range on day 2: 100–352%; on day 3: 40–170%). An increased AMPT-induced prolactin secretion in women has also been observed by Zimmermann et al. (1996) and this gender difference could well be the reason for the larger prolactin increases in our study than those observed by McCann et al. (1992).

As prolactin levels have been reported to be constant between 10 a.m. and 5 p.m. (Sassin et al. 1972), the higher levels on day 2 than on day 3 cannot be ascribed to circadian variation. The decreasing prolactin levels with increasing duration on AMPT may be due to the fact that the rise in prolactin may be related to the rate of DA depletion rather than to a constant amount of DA depletion, and that with more constant DA depletion internal feedback circuits are increasingly able to mitigate the effect of DA depletion on prolactin levels.

Clinical Effects of AMPT

The significant decreases in happiness and increases in tiredness and sleepiness VAS scores on AMPT in our study have also been observed by others in healthy subjects (McCann et al. 1993; Laruelle et al. 1997). The fact that decrease in happiness was highly and significantly correlated to MHPG decrease but not HVA decrease suggests a larger role for NE depletion than for DA depletion.

Moreover, we could not confirm the significant positive correlation between D₂RBP increase and decrease in VAS happiness scores described by Laruelle et al. (1997). This may be due to the fact that not DA but NE depletion seems to be more related to the decrease in

happiness. However, interpretation of our results is limited by: 1) the lower number of subjects reducing the power to detect such correlations; and 2) the lack of a placebo group.

Attentiveness (*d'*), the measure for selective attentiveness of the CPT, decreased significantly on AMPT and this decrease was significantly positively correlated with D₂RBP_{shift}. In parallel, the number of errors of commission increased significantly on AMPT and this increase was significantly positively correlated with D₂RBP_{shift}. These data are in accordance with data showing an improvement in selective attention in healthy subjects after d-amphetamine administration in healthy subjects (Servan-Schreiber et al. 1998). Based on those data and on our study, it seems that increasing DAergic transmission improves and decreasing DAergic transmission worsens selective attention in healthy subjects. Whereas d-amphetamine induced a speeding of reaction time overall and an improvement of accuracy at fast reaction times (Servan-Schreiber et al. 1998), AMPT in our study did not affect reaction time and reduced accuracy by increasing errors of commission.

Since the FTT results in our study were unaffected by AMPT administration, AMPT was found to primarily affect catecholamine transmission in cognitive rather than motor networks. This was similar for d-amphetamine in the study of Servan-Schreiber et al. (1998). However, the lack of any significant change of FTT scores with AMPT-induced DA depletion and with age in our study is in contrast with findings of Volkow et al. (1998) who observed significant and high positive correlations between D₂R availability and FTT scores, both without and with partialing out the significant age effect in their study on both D₂R availability and FTT scores. Given the limited sample size and age range in this study, we do not feel confident that we can rule out an age effect on the FTT scores. The D₂RBP decrease with age is more chronic and likely to be differentially related to synaptic DA levels and DA transmission than the acute D₂RBP increase on AMPT, therefore resulting in a differential relationship with FTT scores. We intend to expand the sample size and age range of healthy subjects to obtain more informative data on these relationships.

We conclude that the noninvasive [¹¹C]raclopride PET protocol used in our study, coupled with relatively brief administration of a relatively low total dose of AMPT, resulted in measurable acute DA depletion that might reflect estimates of synaptic neostriatal DA concentration.

ACKNOWLEDGMENTS

This work was supported by a Young Investigator Award from the National Alliance for Research on Schizophrenia and Affective Disorders to Dr. Verhoeff, by a Postdoctoral Re-

search Fellowship Award from the Ontario Mental Health Foundation to Dr. Verhoeff, and by a Clinician Scientist Award from the Medical Research Council of Canada to Dr. Kapur. The authors gratefully acknowledge Merck & Co., Inc., West Point, Pennsylvania, USA, and Merck Frosst Canada Inc., Point-Claire – Dorval, Quebec, Canada, for providing the AMPT; Anissa Abi-Dargham, M.D., Marc Laruelle, M.D., and Amit Anand, M.D., for sharing scientific information that made valuable contributions to the formulation of the study protocol; Alex Keckojevic, B.Sc., for assistance with subject recruitment; Colleen Millikin, M.Sc., for assistance with cognitive psychological testing; Terry Bell, Kevin Cheung, Steven Dobbin, and Erin Toole for assistance in PET data acquisition; Jean DaSilva, Ph.D., and Alan A. Wilson, Ph.D., for synthesis and plasma analysis of [¹¹C]raclopride; Sylvain Houle, M.D., Ph.D., F.R.C.P.C., for providing the infrastructure enabling us to do the PET studies; Edward Dunn, Ph.D., F.C.A.C.B., for providing the infrastructure enabling us to do the laboratory studies; and Corey Jones, B.A., for the PET Centre computer system's management; staff of the Clinical Investigation Unit, 10th floor, Clarke Division, Centre for Addiction and Mental Health, for support for and management of the subjects during their overnight stay in the psychiatric inpatient unit.

REFERENCES

- Abbott Laboratories (1997): Imx® Prolactin. Abbott Park, IL, Abbott Laboratories, pp 1–11
- Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998): Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. *Am J Psychiatry* 155:761–767
- Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, VanHeertum RL, Gorman JM, Laruelle M (2000): Increased baseline occupancy of D₂ receptors by dopamine in schizophrenia. *Proc Natl Acad Sci U S A* 97: 8104–8109
- Anand A, Darnell A, Miller HL, Berman RM, Capiello A, Oren DA, Woods SW, Charney DS (1999): Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. *Biol Psychiatry* 45:972–978
- Beck AT, Rial WY, Rickels K (1974): Short form of depression inventory cross-validation. *Psychol Rep* 34(3): 1184–1186
- Booij J, Korn P, Linszen DH, van Royen EA (1997): Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. *Eur J Nucl Med* 24:674–677
- Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997): Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. *Proc Natl Acad Sci U S A* 94:2569–2574
- Burger C, Buck A (1997): Requirements and implementation of a flexible kinetic modeling tool. *J Nucl Med* 38:1818–1823
- Camps M, Cortés R, Gueye B, Probst A, Palacios JM (1989):

- Dopamine receptors in human brain: autoradiographic distribution of D₂ sites. *Neuroscience* 28:275–290
- Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, Siegel JL (1990): Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: Study with intravenous midazolam. *J Clin Psychopharmacol* 10:244–251
- Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980): The extrapyramidal symptom rating scale. *Can J Neurol Sci* 7:233
- Conners CK (1995): *Conners' Continuous Performance Test computer program. User's manual.* Toronto, Ontario, Canada, Multi-Health Systems, Inc.
- Costa DC, Verhoeff NPLG, Cullum ID, Ell PJ, Syed GMS, Barrett J, Palazidou E, Toone B, van Royen EA, Bobeldijk M (1990): In vivo characterisation of 3-iodo-6-methoxybenzamide ¹²³I in humans. *Eur J Nucl Med* 16:813–816
- Engelman K, Jequier E, Udenfriend S, Sjoerdsma A (1968): Metabolism of alpha-methyltyrosine in man: Relationship to its potency as an inhibitor of catecholamine biosynthesis. *J Clin Invest* 47:568–576
- Fisher RE, Morris ED, Alpert NM, Fischman AJ (1995): In vivo imaging of neuromodulatory synaptic transmission using PET: A review of relevant neurophysiology. *Hum Brain Mapping* 3:24–34
- Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiack RSJ (1995): Statistical parametric maps in functional imaging: A general linear approach. *Hum Brain Mapping* 2:189–210
- Fujita M, Verhoeff NPLG, Varrone A, Zoghbi SS, Baldwin RM, Jatlow PA, Anderson GM, Seibyl JP, Innis RB (2000): Imaging extrastriatal dopamine D₂ receptor occupancy by endogenous dopamine in healthy humans. *Eur J Pharmacol* 387:179–188
- Ginovart N, Farde L, Halldin C, Swahn CG (1997): Effect of reserpine-induced depletion of synaptic dopamine on [¹¹C]raclopride binding to D₂-dopamine receptors in the monkey brain. *Synapse* 25:321–325
- Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997): Parametric imaging of ligand-receptor binding in PET using a simplified reference tissue model. *Neuroimage* 6:279–287
- Hume SP, Opacka-Juffry J, Myers R, Ahier RG, Ashworth S, Brooks DJ, Lammertsma AA (1995): Effect of L-dopa and 6-hydroxydopamine on [¹¹C]raclopride binding in rat striatum, quantified using PET. *Synapse* 21:45–53
- Ito H, Hietala J, Blomqvist G, Halldin C, Farde L (1998): Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [¹¹C]raclopride binding. *J Cereb Blood Flow Metab* 18:941–950
- Ito K, Haga T, Lameh J, Sadee W (1999): Sequestration of dopamine D₂ receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. *Eur J Biochem* 260:112–119
- Iwata SI, Izumi K, Nomoto M (1992): Upregulation of postsynaptic dopamine receptors in the striatum does not influence haloperidol-induced catalepsy in mice. *Pharmacol Biochem Behav* 42:803–808
- Khan ZU, Gutierrez A, Martin R, Penafiel A, Rivera A, De La Calle A (1998): Differential regional and cellular distribution of dopamine D₂-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. *J Comp Neurol* 402:353–371
- Lammertsma AA, Hume SP (1996): Simplified reference tissue model for PET receptor studies. *Neuroimage* 4:153–158
- Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RSJ (1996): Comparison of methods for analysis of clinical [¹¹C]raclopride studies. *J Cereb Blood Flow Metab* 16:42–52
- Laruelle M (2000): Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. *J Cereb Blood Flow Metab* 20:423–451
- Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB (1997): Imaging D₂ receptor occupancy by endogenous dopamine in humans. *Neuropsychopharmacology* 17:162–174
- Lewis DA, Melchitzky DS, Haycock JW (1993): Four isoforms of tyrosine hydroxylase are expressed in human brain. *Neuroscience* 54:477–492
- Martres MP, Bouthenet ML, Sales N, Sokoloff P, Schwartz JC (1985): Widespread distribution of brain dopamine receptors evidenced with [¹²⁵I]iodosulpride, a highly selective ligand. *Science* 228:752–755
- McCann UD, Penetar DM, Shaham Y, Thorne DR, Gillin C, Sing HC, Thomas MA, Belenky G (1992): Sleep deprivation and impaired cognition. Possible role of brain catecholamines. *Biol Psychiatry* 31:1082–1097
- McCann UD, Penetar DM, Shaham Y, Thorne DR, Sing HC, Thomas MA, Gillin C, Belenky G (1993): Effects of catecholamine depletion on alertness and mood in rested and sleep deprived normal volunteers. *Neuropsychopharmacology* 8:345–356
- McNair DM, Lorr M, Droppleman LF (1981): *POMS Manual*, 2nd ed. San Diego, CA, Educational and Industrial Testing Service
- Meyer JH, Gunn RN, Myers R, Grasby PM (1999): Assessment of spatial normalization of PET ligand images using ligand-specific templates. *Neuroimage* 9:545–553
- Mignot E, Laude D (1985): Study of dopamine turnover by monitoring the decline of dopamine metabolites in rat CSF after alpha-methyl-p-tyrosine. *J Neurochem* 45:1527–1533
- Moresco RM, Loc'h C, Ottaviani M, Guibert B, Levie V, Maziere M, Fazio F, Maziere B (1999): Effects of dopamine on the in vivo binding of dopamine D₂ receptor radioligands in rat striatum. *Nucl Med Biol* 26:91–98
- Narang N, Wamsley JK (1995): Time dependent changes in DA uptake sites, D₁ and D₂ receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain. *J Chem Neuroanat* 9:41–53
- Reitan RM, Wolfson D (1985): *The Halstead-Reitan Neuropsychological Test Battery.* Tucson, AZ, Neuropsychology Press
- Richfield EK, Young AB, Penney JB (1986): Properties of D₂ dopamine receptor autoradiography: High percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections. *Brain Res* 383:121–128
- Ross SB, Jackson DM (1989): Kinetic properties of the accu-

- mulation of ³H-raclopride in the mouse brain *in vivo*. *Arch Pharmacol* 340:6–12
- Roy SD, McKay G, Hawes EM, Midha KK (1984): Gas chromatographic quantitation of methoxyamphetamine and three of its metabolites in plasma. *J Chromatogr* 310:307–317
- Sassin JF, Frantz AG, Weitzman ED, Kapen S (1972): Human prolactin: 24-hour pattern with increased release during sleep. *Science* 177:1205–1207
- Servan-Schreiber D, Carter CS, Bruno RM, Cohen JD (1998): Dopamine and the mechanisms of cognition. II. D-amphetamine effects in human subjects performing a selective attention task. *Biol Psychiatry* 43:723–729
- Sibley DR, De Lean A, Creese I (1982): Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D₂ dopamine receptor. *J Biol Chem* 257:6351–6361
- Tabachnick BG, Fidell LS (1996): *Using Multivariate Statistics*, 3rd ed. California State University, Northridge, Harper Collins College Publishers, pp 57–126
- Takahashi S, Godse DD, Warsh JJ, Stancer HC (1977): A gas chromatographic-mass spectrometric (GC-MS) assay for 3-methoxy-4-hydroxyphenylethyleneglycol and vanyl-mandelic acid in human serum. *Clin Chim Acta* 81:183–192
- Verhoeff NPLG (1999): Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. *Psychopharmacology* 147:217–249
- Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, Burr G, Cooper T, Wolf AP (1994): Imaging endogenous dopamine competition with [¹¹C]raclopride in the human brain. *Synapse* 16:255–262
- Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, Hitzemann R, Smith G, Logan J (1998): Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. *Am J Psychiatry* 155:344–349
- Wang GJ, Volkow ND, Fowler JS, Wolf AP, MacGregor RR, Shea CE, Schlyer DJ, Hitzemann RJ (1993): Comparison of two PET radioligands for imaging extrastriatal dopamine receptors in the human brain. *Synapse* 15:246–249
- Wang GJ, Volkow ND, Levy AV, Fowler JS, Logan J, Alexoff D, Hitzemann RJ, Schlyer DJ (1996a): MRI-PET image coregistration for quantification of striatal dopamine D₂ receptors. *J Comput Assist Tomogr* 20:423–428
- Wang GJ, Volkow ND, Fowler JS, Logan J, Gur R, Netusil N, Hitzemann RJ, Pappas N (1996b): Age associated decrements in dopamine D₂ receptors in thalamus and in temporal insula of human subjects. *Life Sci* 59:PL31–PL35
- Warsh JJ, Godse DD, Li PP (1987): Quantitation of catecholamine metabolites by gas chromatography-mass spectrometry with selected ion monitoring. *Methods Enzymol* 142:571–582
- Weeks RA, Cunningham VJ, Piccini P, Waters S, Harding AE, Brooks DJ (1997): ¹¹C-diprenorphine binding in Huntington's disease: A comparison of region of interest analysis with statistical parametric mapping. *J Cereb Blood Flow Metab* 17:943–949
- Zimmermann RC, Krahn L, Klee G, Lu PY, Ory SJ, Lin SC (1996): The impact of gender on alpha-methyl-paratyrosine mediated changes in prolactin secretion and 6-hydroxymelatonin sulfate excretion. *Psychoneuroendocrinology* 21:469–478